Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity.

METHODS: Human eosinophil EoL-1 cells were treated with Bucladesine sodium (10-100 µM) for 8 days and activity was measured using PKA assay.
RESULTS: Proliferation of EoL-1 cells treated with Bucladesine sodium increased in a time-dependent manner. [1]
METHODS: PC12 cells were treated with Bucladesine sodium (1 mM) for 72 h. TNF-α levels were measured by ELISA assay.
RESULTS: Bucladesine sodium increased the activity of PKA. [2]

METHODS: To study the anti-inflammatory activity in vivo, Bucladesine sodium (0.24-0.7 µg/kg) was administered intraperitoneally to a mouse model of copper pine demyelination once daily for seven days.
RESULTS: Bucladesine had a protective effect on myelin formation. Enhanced intracellular cAMP prevented demyelination and exerted anti-inflammatory and anti-apoptotic properties in a mouse model of copper pine demyelination. [3]
METHODS: To investigate the effects on liver injury, Bucladesine sodium (0.5-500 mg/kg) was intraperitoneally injected into C57BL/6J jcl mice, and liver injury was induced by the intravenous injection of rTNF-α (1.0 µg/kg) and intraperitoneal injection of D-gal (500 mg/kg) after 1 h. The RESULTS showed that Bucladesine protected against hepatic injury in C57BL/6J jcl mice.
RESULTS: Bucladesine protected mice from TNF-α/D-gal-induced liver injury.Bucladesine significantly enhanced the expression of Hsp70 in hepatocytes of D-gal/TNFα-injected mice, which was closely related to the inhibition of liver injury. [4]

Animal: Mice. Formulation: water/DMSO (9:1). Dosages: 600 nM. Administration: i.p.